Repare Therapeutics Beheer
Beheer criteriumcontroles 2/4
De CEO Repare Therapeutics is Lloyd Segal, benoemd in Sep2016, heeft een ambtstermijn van 8.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.99M, bestaande uit 12.3% salaris en 87.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.28% van de aandelen van het bedrijf, ter waarde $ 421.96K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.5 jaar en 4.7 jaar.
Belangrijke informatie
Lloyd Segal
Algemeen directeur
US$5.0m
Totale compensatie
| Percentage CEO-salaris | 12.3% |
| Dienstverband CEO | 8.2yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | 5.5yrs |
| Gemiddelde ambtstermijn bestuur | 4.7yrs |
Recente managementupdates
Recent updates
There's No Escaping Repare Therapeutics Inc.'s (NASDAQ:RPTX) Muted Revenues Despite A 35% Share Price Rise
Oct 05
Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data
Aug 30Will Repare Therapeutics (NASDAQ:RPTX) Spend Its Cash Wisely?
Jul 12Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues
May 01Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet
Mar 12We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully
Feb 15Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth
Dec 20Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
Oct 24New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)
Aug 14Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week
May 14Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results
May 12Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough
May 08Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%
Mar 03Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Oct 27Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
Sep 07Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M
Aug 04Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go
Jun 27Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Jun 24Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans
Mar 02We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn
Oct 14We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Apr 16Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?
Mar 12Are Institutions Heavily Invested In Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares?
Feb 08
Repare Therapeutics: CRISPR-Enabled Technology Might Unlock New Therapies
Dec 28Trade Alert: The Executive VP & Head of Business & Corporate Development Of Repare Therapeutics Inc. (NASDAQ:RPTX), Kim Seth, Has Sold Some Shares Recently
Dec 21Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$69m |
| Mar 31 2024 | n/a | n/a | -US$46m |
| Dec 31 2023 | US$5m | US$615k | -US$94m |
| Sep 30 2023 | n/a | n/a | -US$97m |
| Jun 30 2023 | n/a | n/a | -US$3m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$4m | US$592k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$26m |
| Jun 30 2022 | n/a | n/a | -US$132m |
| Mar 31 2022 | n/a | n/a | -US$120m |
| Dec 31 2021 | US$4m | US$572k | -US$107m |
| Sep 30 2021 | n/a | n/a | -US$94m |
| Jun 30 2021 | n/a | n/a | -US$77m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$5m | US$505k | -US$53m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$35m |
| Dec 31 2019 | US$2m | US$430k | -US$27m |
Compensatie versus markt: De totale vergoeding ($USD 4.99M ) Lloyd } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.48M ).
Compensatie versus inkomsten: De vergoeding van Lloyd is gestegen terwijl het bedrijf verliesgevend is.
CEO
Lloyd Segal (60 yo)
8.2yrs
Tenure
US$4,991,804
Compensatie
Mr. Lloyd Mitchell Segal serves as Director at HotKnot Therapeutics, Inc. Mr. Segal has been the Chief Executive Officer, President and Director of Repare Therapeutics Inc. since September 2016. Mr. Segal...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 8.2yrs | US$4.99m | 0.28% $ 422.0k | |
| Executive VP & CFO | 5.1yrs | US$1.93m | 0.034% $ 51.6k | |
| Executive VP & Chief Medical Officer | 5.5yrs | US$2.09m | 0.47% $ 715.2k | |
| Co-Founder | no data | geen gegevens | geen gegevens | |
| Co-Founder | no data | geen gegevens | geen gegevens | |
| Co-Founder | no data | geen gegevens | geen gegevens | |
| Executive VP & Chief Scientific Officer | 5.5yrs | US$1.83m | 0.098% $ 148.7k | |
| Executive Vice President of Human Resource | 1.5yrs | geen gegevens | 0.0037% $ 5.6k | |
| Executive Vice President of Discovery | 8.4yrs | geen gegevens | 0.055% $ 83.8k | |
| Executive VP | 2.8yrs | geen gegevens | 0.0092% $ 14.0k |
5.5yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van RPTX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 8.2yrs | US$4.99m | 0.28% $ 422.0k | |
| Independent Director | 4.4yrs | US$274.74k | 0.0094% $ 14.3k | |
| Independent Director | 5.2yrs | US$265.41k | 0% $ 0 | |
| Independent Director | 1.4yrs | US$664.86k | 0% $ 0 | |
| Independent Director | less than a year | geen gegevens | geen gegevens | |
| Independent Director | 5yrs | US$265.31k | 0% $ 0 | |
| Independent Chairman | 3.2yrs | US$291.49k | 0.018% $ 26.9k | |
| Independent Director | 5.7yrs | US$272.99k | 0.019% $ 28.6k |
4.7yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van RPTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).